What the evidence actually shows

Does ChondroFiller hold up over time? The short answer, based on published clinical data, is yes — and the gains are larger than the threshold that separates meaningful recovery from statistical noise.

Across four knee studies, patients consistently achieved IKDC score improvements of approximately 30 points over 12 months. The benchmark that matters here is 16.7 points — the Minimal Clinically Important Difference (MCID) for the IKDC scale, the threshold below which a change is unlikely to be felt as real improvement in daily life. Every study in the reviewed set cleared that bar comfortably.

Structural repair, measured by MOCART MRI scoring, clustered between 81.6 and 84.3 at 12 months across European knee studies — a range indicating greater than 80% defect filling with good integration into surrounding native cartilage. One study traced MOCART from 65.3 at four weeks to 81.6 at one year, showing the scaffold matures progressively rather than reaching peak repair in the early weeks.

The 36-month picture is provided by the Jerosch et al. prospective PMCF study, which recorded a mean IKDC gain of 32.4 points that was sustained — and marginally increased — at the three-year follow-up, with patients reaching an absolute IKDC score of 80.1. Gains were not eroded over time.

This is an emerging evidence base, and it carries limitations worth naming plainly: the studies sit within a manufacturer-sponsored Post-Market Clinical Follow-up framework, and independent randomised controlled trial comparisons are not yet available. That does not invalidate the findings, but it is the appropriate context in which to read them.

IKDC scores from baseline to 36 months

The Jerosch et al. prospective PMCF study tracks the IKDC trajectory most completely, recording a mean gain of 32.4 points — a figure that sits fractionally above the approximate 30-point average seen across the four knee studies. What the three-year follow-up adds is not simply a larger number but a direction of travel: scores at 36 months were marginally higher than at 12 months, meaning the improvement had not plateaued or eroded but continued to consolidate.

Patients in the Jerosch cohort reached an absolute IKDC score of 80.1 at the three-year mark. On a 100-point scale where 100 represents normal knee function, 80.1 reflects high functional recovery — not a partial reduction in symptoms but a return to near-normal activity levels for a majority of participants.

Durability is the critical variable at 36 months. Many cartilage interventions produce measurable early gains; the clinically harder question is whether those gains hold. In this cohort they did — and the 32.4-point mean comfortably exceeds twice the 16.7-point minimum threshold at which patients are considered to notice a real-world difference in daily function.

Consistency across the broader study set reinforces the single-cohort finding. Four distinct knee studies report gains in the same approximate range, suggesting the trajectory is a product of the treatment mechanism rather than an artefact of one investigator group or patient population.

MOCART scores and what they show about repair quality

MOCART — Magnetic Resonance Observation of Cartilage Repair Tissue — is the imaging-based counterpart to patient-reported measures such as the IKDC. Scored out of 100, it rates how completely the repaired area has filled, how well the new tissue integrates with the surrounding native cartilage, and how closely the surface contour matches the healthy joint. A score above 80 is widely regarded in the literature as indicating good-to-excellent repair.

At 12 months, European knee studies of ChondroFiller return scores clustered between 81.6 and 84.3 — above that threshold, indicating the repaired tissue has filled more than 80% of the defect with sound lateral and deep integration into surrounding structures.

The more instructive finding is the trajectory that leads to those figures. In one key study, MOCART stood at 65.3 just four weeks after treatment, rising to 81.6 by month twelve. That progression matters: it demonstrates the scaffold is still maturing structurally at the 12-month mark rather than reaching peak repair in the early weeks. Biological remodelling — the gradual replacement of the collagen matrix by patient-derived, hyaline-like cartilage — continues well into the first year.

Across all studied joints, published MOCART scores range from 70 to 87, reflecting variability by site, defect characteristics, and individual patient factors; the lower end of that range should not in itself imply poor repair. What happens to structural scores beyond year one remains to be reported in the literature. What the 12-month data establish is a structural rationale that runs parallel to the functional improvements documented in IKDC scores over the same period.

Why the scaffold biology explains the score trajectory

Once injected, the liquid collagen solution gels within minutes, forming a stable three-dimensional scaffold that holds the repair site together while the body begins its own response. ChondroFiller is acellular — it contains no donor or laboratory-grown cells — so the repair work is done entirely by the patient's own progenitor cells, which migrate into the matrix, mature into chondrocytes, and progressively lay down hyaline-like tissue as the scaffold is resorbed.

This biological sequence unfolds over months, not days, and that lag is precisely what the imaging data reflect. A MOCART reading taken at four weeks captures the scaffold in its early stabilising role; the structural scores documented at 12 months represent a repair tissue that has had time to differentiate and integrate. The continued marginal improvement in functional scores between one and three years is consistent with ongoing remodelling rather than a plateau reached early and held by luck.

The 3-D collagen matrix is central to this outcome. Without a structural scaffold, bone-marrow stimulation techniques such as microfracture produce a blood clot at the defect site that tends to mature into fibrocartilage — a mechanically inferior tissue type — rather than the more durable, hyaline-like repair supported by a defined collagen framework. That distinction in tissue type maps directly onto the difference in structural scores between the two approaches.

Beyond the knee: hip and ankle data in context

The evidence base extends beyond the knee. In hip applications, published series report a mean Harris Hip Score improvement of approximately 33 points — a gain large enough to shift a patient from the poor-to-fair functional range into good territory on a scale where scores of 90 and above are considered excellent. That figure is clinically meaningful, but it sits within a body of data that is less granular than the four-study knee series: detailed IKDC or MOCART analyses at comparable follow-up depth have not been published for the hip at the same scale. Ankle, shoulder, and smaller-joint applications form part of the broader global case experience — across more than 19,000 procedures to date — yet peer-reviewed reporting for those sites remains limited. The 12- and 36-month outcome figures central to this article are specific to knee applications; the hip and ankle data are supportive but should be treated as preliminary rather than equivalent in evidence quality.

Who these outcomes apply to — andwho they may not

Aggregate trial figures describe what happened across a study population; they do not predict outcomes for any individual patient. Several variables moderate results in ways the published data highlight but cannot fully quantify.

Factors that clinical experience and the available studies identify as influential include:

• Defect size and its location within the joint
• The quality of surrounding cartilage at the time of treatment
• Patient age, activity level, and overall joint health

The four knee studies were conducted within the manufacturer's post-market clinical follow-up programme, and head-to-head randomised controlled trials comparing ChondroFiller with other interventions have not yet been published. The real-world picture spans more than 19,000 procedures globally — a complementary layer of evidence, though case-series data cannot substitute for controlled comparisons. These outcome figures represent the best available published evidence as of the April 2025 Clinical Evaluation Report.

What the data collectively support is a consistent, durable signal for suitable patients — pointing toward a focal, defect-specific scaffold intervention rather than a generic symptom filler. Whether that profile applies to any given individual depends on anatomy, defect characteristics, and clinical history: variables that require direct assessment rather than inference from population averages.